For the quarter ending 2025-09-30, ELAN had -$34M decrease in cash & cash equivalents over the period. $127M in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | - | - | - | 4,439 |
| Cost of sales | - | - | - | 2,003 |
| Gross profit | 607 | 713 | 684 | 2,436 |
| Research and development | 89 | 92 | 94 | 344 |
| Marketing and selling | 220 | 272 | 225 | 809 |
| General and administrative | 131 | 128 | 116 | 505 |
| Interest expense, net of capitalized interest | 52 | 48 | 40 | 235 |
| Other expense, net | 0 | 11 | 12 | -18 |
| Income tax (benefit) expense | -16 | 14 | -7 | 150 |
| Total other significant segment expenses | 476 | 565 | 480 | 2,061 |
| Other expenses (income) | 165 | 137 | 137 | 37 |
| Net income | -34 | 11 | 67 | -8 |
| Depreciation and amortization | 176 | 169 | 161 | 164 |
| Goodwill impairment | - | - | - | 0 |
| Deferred income taxes | - | - | - | -112 |
| Stock-based compensation expense | 17 | 20 | 15 | 15 |
| Asset impairment and write-down charges | 24 | 0 | - | 5 |
| Gain on divestiture | 0 | - | - | 0 |
| Sold portion of royalty revenue | 6 | 4 | - | - |
| Loss on extinguishment of debt | - | - | - | 0 |
| Interest on liability for sale of future revenue | 13 | 7 | - | - |
| Proceeds from interest rate swap settlements | - | - | - | 0 |
| Changes in operating assets and liabilities, net of acquisitions and divestitures | -59 | -52 | 330 | - |
| Other non-cash operating activities, net | -30 | -18 | -10 | 57 |
| Receivables | - | - | - | -12 |
| Inventories | - | - | - | -44 |
| Other assets | - | - | - | -11 |
| Accounts payable and other liabilities | - | - | - | 82 |
| Net cash provided by operating activities | 219 | 237 | -4 | 177 |
| Net purchases of property and equipment and software | 92 | 57 | 65 | 47 |
| Purchases of intangible assets | - | - | - | 6 |
| Cash paid for acquisitions | - | - | - | 36 |
| Proceeds from divestitures | 0 | 0 | 9 | 0 |
| Proceeds from sale of shawnee and speke facilities | - | - | - | 0 |
| Other investing activities, net | 9 | -1 | 2 | 1 |
| Net cash (used for) provided by investing activities | -101 | -56 | -58 | -90 |
| Proceeds from facility-Revolving Credit Facility | 0 | 0 | 125 | 0 |
| Repayments of facility-Revolving Credit Facility | 0 | 0 | 125 | 0 |
| Proceeds from facility-Securitization Facility | 0 | 0 | 125 | 0 |
| Repayments of facility-Securitization Facility | 0 | 85 | 40 | 25 |
| Proceeds from issuance of long-term debt | 0 | - | - | 0 |
| Repayments of long-term borrowings | 188 | 361 | 13 | 13 |
| Funding related to construction of corporate headquarters | - | - | - | 0 |
| Proceeds from sale of future revenue, net of transaction costs | 0 | 290 | - | - |
| Other financing activities, net | 35 | 0 | -20 | 6 |
| Net cash used for financing activities | -153 | -156 | 52 | -32 |
| Effect of exchange rate changes on cash and cash equivalents | 1 | 27 | 29 | -77 |
| Net increase in cash and cash equivalents | -34 | 52 | 19 | -22 |
| Cash and cash equivalents at beginning of period | 539 | 487 | 468 | 490 |
| Cash and cash equivalents at end of period | 505 | 539 | 487 | 468 |
Elanco Animal Health Inc (ELAN)
Elanco Animal Health Inc (ELAN)